Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 8:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 26 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: DDR Clear all
Completed Not applicable Interventional

Collaborative Care for Depression and Diabetic Retinopathy in African Americans

NCT02121340
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Behavioral Activation
Behavioral
Lead sponsor
Thomas Jefferson University
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Sep 3, 2026, 8:40 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

NCT04052204
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
avelumab, Bempegaldesleukin, talazoparib, enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 3, 2026, 8:40 AM EDT
Completed No phase listed Observational

Tissue Collection for Correlation Between ATM Alterations by Next-Generation Sequencing and ATM Loss-of-Protein

NCT04976803
View directory record Official record
Conditions
Solid Tumor, Unspecified, Adult
Interventions
Determination of ATM alteration status.
Other
Lead sponsor
Artios Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 31, 2022 · Synced Sep 3, 2026, 8:40 AM EDT
Completed Phase 1 Interventional

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

NCT04095273
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Elimusertib (BAY1895344), Pembrolizumab (Keytruda®)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Palo Alto, California • New Haven, Connecticut • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 3, 2026, 8:40 AM EDT
Completed Phase 2 Interventional

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

NCT03263650
View directory record Official record
Conditions
Prostate Cancer Aggressiveness, Prostate Carcinoma
Interventions
Cabazitaxel, Carboplatin, Prednisone 5Mg, Olaparib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 3, 2026, 8:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Adherence and Health Effects of Video Dance in Postmenopausal Women

NCT01443455
View directory record Official record
Conditions
Post Menopausal
Interventions
videodance, Brisk Walking, delayed entry control
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years to 65 Years · Female only
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Sep 3, 2026, 8:40 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases

NCT04711824
View directory record Official record
Conditions
Breast Cancer, Brain Metastases, Adult
Interventions
Olaparib, Stereotactic Radiosurgery, Durvalumab, Physicians Choice systemic chemotherapy
Drug · Radiation
Lead sponsor
Colette Shen
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Birmingham, Alabama • Hollywood, Florida • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 3, 2026, 8:40 AM EDT
Completed Not applicable Interventional

Ayurveda Diet & Lifestyle Protocol for Type 2 Diabetes: A Feasibility Study

NCT07400276
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Maharishi Ayurveda Lifestyle Program
Behavioral
Lead sponsor
Maharishi International University
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 3, 2026, 8:40 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

NCT04266912
View directory record Official record
Conditions
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Avelumab, Berzosertib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 3, 2026, 8:40 AM EDT
Recruiting Not applicable Interventional

Clinical Utility of Portable Dynamic Chest X Ray (DDR) in the ICU

NCT06538376
View directory record Official record
Conditions
Pulmonary Edema, Pneumonia, Atelectasis, Pleural Effusion, Acute Rejection of Lung Transplant (Disorder), Airway Obstruction, Rib Fractures, Acute Copd Exacerbation, Asthma COPD, Pulmonary Embolism, Hemothorax, Pneumothorax, Mesothelioma, Diaphragmatic Paralysis
Interventions
Portable Dynamic Digital Radiography (DDR)
Diagnostic Test
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 3, 2026, 8:40 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

NCT04821622
View directory record Official record
Conditions
Prostate Cancer
Interventions
talazoparib plus enzalutamide, Placebo plus enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
46
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 3, 2026, 8:40 AM EDT
Completed Phase 1 Interventional

A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).

NCT03022409
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Ceralasertib, Olaparib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Sep 3, 2026, 8:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Accelerometer-linked Online Intervention to Promote Physical Activity in Adolescents

NCT02425384
View directory record Official record
Conditions
Health Behavior, Adolescent Behavior, Motivation
Interventions
Intervention Group (motivational website, activity meter), Active Control (active video game, activity meter), Passive Control (activity meter)
Behavioral · Other
Lead sponsor
HopeLab Foundation
Other
Eligibility
11 Years to 14 Years
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Mountain View, California • Vista, California • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 3, 2026, 8:40 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

NCT01514864
View directory record Official record
Conditions
Carcinoma, Non-small Cell Lung
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 3, 2026, 8:40 AM EDT
Completed Phase 1 Interventional

First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas

NCT03188965
View directory record Official record
Conditions
Advanced Solid Tumor, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Interventions
Elimusertib (BAY1895344)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
14
States / cities
Duarte, California • Tampa, Florida • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Sep 3, 2026, 8:40 AM EDT
Active, not recruiting Phase 2 Interventional

Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations

NCT03609216
View directory record Official record
Conditions
Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
Interventions
Gemcitabine Hydrochloride, Cisplatin, Pegfilgrastim, Conventional Surgery, Radical Cystectomy, Chemoradiotherapy
Drug · Biological · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
424
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 293 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 3, 2026, 8:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Family Exergaming: A Research Study Testing a Videogame Intervention to Increase Physical Activity for Families

NCT00889122
View directory record Official record
Conditions
Obesity
Interventions
Exergame (DDR)
Behavioral
Lead sponsor
MaineHealth
Other
Eligibility
9 Years to 17 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Scarborough, Maine
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Sep 3, 2026, 8:40 AM EDT
Completed Not applicable Interventional

Dance Dance Revolution (DDR) in Type 2 Diabetes

NCT00851019
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
DDR, Treadmill
Behavioral
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Sep 3, 2026, 8:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers

NCT04209595
View directory record Official record
Conditions
Small Cell Lung Cancer, Extra-Pulmonary Small Cell Carcinomas
Interventions
PLX038, Rucaparib, Ondansetron
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 3, 2026, 8:40 AM EDT
Active, not recruiting Phase 2 Interventional

9-ING-41 in Patients With Advanced Cancers

NCT03678883
View directory record Official record
Conditions
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
Interventions
9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin., Lomustine, Carboplatin., Nab paclitaxel., Paclitaxel., Gemcitabine - 28 day cycle, Irinotecan
Drug
Lead sponsor
Actuate Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
40
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 3, 2026, 8:40 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

NCT03330405
View directory record Official record
Conditions
Avelumab in Combination With Talazoparib Will be Investigated in Patients With Locally Advanced (Primary or Recurrent) or Metastatic Solid Tumors
Interventions
Avelumab Phase 1b, Talazoparib Phase 1b, Avelumab Phase 2, Talazoparib Phase 2
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
38
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Sep 3, 2026, 8:40 AM EDT
Recruiting Phase 1 Interventional

A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

NCT07356453
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
FORX-428
Drug
Lead sponsor
FoRx Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Palo Alto, California • San Francisco, California • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Sep 3, 2026, 8:40 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of LP-184 in Patients With Advanced Solid Tumors

NCT05933265
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation
Interventions
LP-184, Olaparib, Nivolumab & Ipilimumab
Drug
Lead sponsor
Lantern Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Springdale, Arkansas • Indianapolis, Indiana • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 3, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

NCT03207347
View directory record Official record
Conditions
Mesothelioma, Uveal Melanoma, Renal Cell Carcinoma, Cholangiocarcinoma
Interventions
Niraparib
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
3
States / cities
Gainesville, Florida • Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Sep 3, 2026, 8:40 AM EDT